Chemical Reviews pubs.acs.

org/CR Review

(146) Zheng, G.; Zhou, D.; Zhang, X.; Wang, Y.; Chang, J. (162) Shibata, N.; Miyamoto, N.; Nagai, K.; Shimokawa, K.;
Compounds that induce degradation of anti-apoptotic bcl-2 family Sameshima, T.; Ohoka, N.; Hattori, T.; Imaeda, Y.; Nara, H.; Cho,
proteins and the uses thereof. WO2017184995A1, 2017. N.; et al. Development of Protein Degradation Inducers of Oncogenic
(147) Quintas-Cardama, A.; Cortes, J. Molecular Biology of Bcr- BCR-ABL Protein by Conjugation of ABL Kinase Inhibitors and IAP
Abl1-Positive Chronic Myeloid Leukemia. Blood 2009, 113, 1619− Ligands. Cancer Sci. 2017, 108, 1657−1666.
1630. (163) Lai, A. C.; Toure, M.; Hellerschmied, D.; Salami, J.; Jaime-
(148) Manley, P. W.; Cowan-Jacob, S. W.; Buchdunger, E.; Fabbro, Figueroa, S.; Ko, E.; Hines, J.; Crews, C. M. Modular PROTAC
D.; Fendrich, G.; Furet, P.; Meyer, T.; Zimmermann, J. Imatinib: A Design for the Degradation of Oncogenic BCR-ABL. Angew. Chem.,
Selective Tyrosine Kinase Inhibitor. Eur. J. Cancer 2002, 38, S19−S28. Int. Ed. 2016, 55, 807−810.
(149) Apperley, J. F. Mechanisms of Resistance to Imatinib in (164) Burslem, G. M.; Schultz, A. R.; Bondeson, D. P.; Eide, C. A.;
Chronic Myeloid Leukaemia. Lancet Oncol. 2007, 8, 1018−1029. Savage Stevens, S. L.; Druker, B. J.; Crews, C. M. Cancer Res. 2019,
(150) Soverini, S.; Colarossi, S.; Gnani, A.; Rosti, G.; Castagnetti, F.; 79, 4744−4753.
Poerio, A.; Iacobucci, I.; Amabile, M.; Abruzzese, E.; Orlandi, E.; et al. (165) Chapman, P. B.; Hauschild, A.; Robert, C.; Haanen, J. B.;
Contribution of ABL Kinase Domain Mutations to Imatinib Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.;
Resistance in Different Subsets of Philadelphia-Positive Patients: By et al. Improved Survival with Vemurafenib in Melanoma with BRAF
the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. V600E Mutation. N. Engl. J. Med. 2011, 364, 2507−2516.
Cancer Res. 2006, 12 (24), 7374−7379. (166) Yang, H.; Higgins, B.; Kolinsky, K.; Packman, K.; Go, Z.; Iyer,
(151) Blair, J. A.; Rauh, D.; Kung, C.; Yun, C.-H.; Fan, Q.-W.; Rode, R.; Kolis, S.; Zhao, S.; Lee, R.; Grippo, J. F.; et al. RG7204
H.; Zhang, C.; Eck, M. J.; Weiss, W. A.; Shokat, K. M. Structure- (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent
Guided Development of Affinity Probes for Tyrosine Kinases Using Antitumor Activity in Preclinical Melanoma Models. Cancer Res.
Chemical Genetics. Nat. Chem. Biol. 2007, 3, 229−238. 2010, 70, 5518−5527.
(152) Blay, J. Y.; von Mehren, M. Nilotinib: A Novel, Selective (167) Tsai, J.; Lee, J. T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.;
Tyrosine Kinase Inhibitor. Semin. Oncol. 2011, 38, S3−S9. Bremer, R.; Gillette, S.; Kong, J.; Haass, N. K.; et al. Discovery of a
(153) Das, J.; Chen, P.; Norris, D.; Padmanabha, R.; Lin, J.; Moquin, Selective Inhibitor of Oncogenic B-Raf Kinase with Potent
R. V.; Shen, Z.; Cook, L. S.; Doweyko, A. M.; Pitt, S.; et al. 2- Antimelanoma Activity. Proc. Natl. Acad. Sci. U. S. A. 2008, 105,
Aminothiazole as a Novel Kinase Inhibitor Template. Structure- 3041−3046.
Activity Relationship Studies toward the Discovery of N-(2-Chloro-6- (168) Nazarian, R.; Shi, H.; Wang, Q.; Kong, X.; Koya, R. C.; Lee,
methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4- H.; Chen, Z.; Lee, M.-K.; Attar, N.; Sazegar, H.; et al. Melanomas
pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS- Acquire Resistance to B-RAF(V600E) Inhibition by RTK or N-RAS
354825) as a Potent pan-Src Kinase Inhibitor. J. Med. Chem. 2006, Upregulation. Nature 2010, 468, 973−977.
49, 6819−6832. (169) Van Allen, E. M.; Wagle, N.; Sucker, A.; Treacy, D. J.;
(154) Golas, J. M.; Arndt, K.; Etienne, C.; Lucas, J.; Nardin, D.; Johannessen, C. M.; Goetz, E. M.; Place, C. S.; Taylor-Weiner, A.;
Whittaker, S.; Kryukov, G. V.; et al. The Genetic Landscape of
Gibbons, J.; Frost, P.; Ye, F.; Boschelli, D. H.; Boschelli, F. SKI-606, a
Clinical Resistance to RAF Inhibition in Metastatic Melanoma. Cancer
4-Anilino-3-quinolinecarbonitrile Dual Inhibitor of Src and Abl
Discovery 2014, 4, 94−109.
Kinases, Is a Potent Antiproliferative Agent against Chronic
(170) Arozarena, I.; Wellbrock, C. Overcoming Resistance to BRAF
Myelogenous Leukemia Cells in Culture and Causes Regression of
Inhibitors. Ann. Transl. Med. 2017, 5, 387−399.
K562 Xenografts in Nude Mice. Cancer Res. 2003, 63, 375−381.
(171) Griffin, M.; Scotto, D.; Josephs, D. H.; Mele, S.; Crescioli, S.;
(155) Huang, W. S.; Metcalf, C. A.; Sundaramoorthi, R.; Wang, Y.;
Bax, H. J.; Pellizzari, G.; Wynne, M. D.; Nakamura, M.; Hoffmann, R.
Zou, D.; Thomas, R. M.; Zhu, X.; Cai, L.; Wen, D.; Liu, S.; et al. M.; et al. BRAF Inhibitors: Resistance and the Promise of
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl- Combination Treatments for Melanoma. Oncotarget 2017, 8,
N-{4-[(4-methylpiperazin-1-y l)methyl]-3-(trifluoromethyl)phenyl}- 78174−78192.
benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of (172) Kirouac, D. C.; Schaefer, G.; Chan, J.; Merchant, M.; Orr, C.;
Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the Huang, S. A.; Moffat, J.; Liu, L.; Gadkar, K.; Ramanujan, S. Clinical
T315I Gatekeeper Mutant. J. Med. Chem. 2010, 53, 4701−4719. Responses to ERK Inhibition in BRAF(V600E)-Mutant Colorectal
(156) Adrian, F. J.; Ding, Q.; Sim, T.; Velentza, A.; Sloan, C.; Liu, Cancer Predicted Using a Computational Model. npj Syst. Biol. Appl.
Y.; Zhang, G.; Hur, W.; Ding, S.; Manley, P.; et al. Allosteric 2017, 3, 14.
Inhibitors of Bcr-Abl-Dependent Cell Proliferation. Nat. Chem. Biol. (173) Yao, Z.; Gao, Y.; Su, W.; Yaeger, R.; Tao, J.; Na, N.; Zhang, Y.;
2006, 2, 95−102. Zhang, C.; Rymar, A.; Tao, A.; et al. RAF Inhibitor PLX8394
(157) Wylie, A. A.; Schoepfer, J.; Jahnke, W.; Cowan-Jacob, S. W.; Selectively Disrupts BRAF Dimers and RAS-Independent BRAF-
Loo, A.; Furet, P.; Marzinzik, A. L.; Pelle, X.; Donovan, J.; Zhu, W.; Mutant-Driven Signaling. Nat. Med. 2019, 25, 284−291.
et al. The Allosteric Inhibitor ABL001 Enables Dual Targeting of (174) Byrd, J. C.; Furman, R. R.; Coutre, S. E.; Flinn, I. W.; Burger,
BCR-ABL1. Nature 2017, 543, 733−737. J. A.; Blum, K. A.; Grant, B.; Sharman, J. P.; Coleman, M.; Wierda, W.
(158) Zhang, J.; Adrian, F. J.; Jahnke, W.; Cowan-Jacob, S. W.; Li, A. G.; et al. Targeting BTK with Ibrutinib in Relapsed Chronic
G.; Iacob, R. E.; Sim, T.; Powers, J.; Dierks, C.; Sun, F.; et al. Lymphocytic Leukemia. N. Engl. J. Med. 2013, 369, 32−42.
Targeting Bcr-Abl by Combining Allosteric with ATP-Binding-Site (175) Pan, Z.; Scheerens, H.; Li, S. J.; Schultz, B. E.; Sprengeler, P.
Inhibitors. Nature 2010, 463, 501−506. A.; Burrill, L. C.; Mendonca, R. V.; Sweeney, M. D.; Scott, K. C.;
(159) Fabbro, D.; Manley, P. W.; Jahnke, W.; Liebetanz, J.; Grothaus, P. G.; et al. Discovery of Selective Irreversible Inhibitors for
Szyttenholm, A.; Fendrich, G.; Strauss, A.; Zhang, J.; Gray, N. S.; Bruton’s Tyrosine Kinase. ChemMedChem 2007, 2, 58−61.
Adrian, F.; et al. Inhibitors of the Abl Kinase Directed at Either the (176) Bender, A. T.; Gardberg, A.; Pereira, A.; Johnson, T.; Wu, Y.;
ATP- or Myristate-Binding Site. Biochim. Biophys. Acta, Proteins Grenningloh, R.; Head, J.; Morandi, F.; Haselmayer, P.; Liu-Bujalski,
Proteomics 2010, 1804, 454−462. L. Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551
(160) Schoepfer, J.; Jahnke, W.; Berellini, G.; Buonamici, S.; Cotesta, and Prevent Phosphorylation Determines Potency for Inhibition of Fc
S.; Cowan-Jacob, S. W.; Dodd, S.; Drueckes, P.; Fabbro, D.; Gabriel, Receptor but not B-Cell Receptor Signaling. Mol. Pharmacol. 2017,
T.; et al. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of 91, 208−219.
the Tyrosine Kinase Activity of BCR-ABL1. J. Med. Chem. 2018, 61, (177) Honigberg, L. A.; Smith, A. M.; Sirisawad, M.; Verner, E.;
8120−8135. Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D. H.; Miller, R. A.;
(161) Nussinov, R.; Tsai, C. J. Allostery in Disease and in Drug et al. The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell
Discovery. Cell 2013, 153, 293−305. Activation and is Efficacious in Models of Autoimmune Disease and

AV https://dx.doi.org/10.1021/acs.chemrev.0c00383
Chem. Rev. XXXX, XXX, XXX−XXX